Pangaea Oncology, S.A. Stock

Equities

PANG

ES0105221008

Biotechnology & Medical Research

Delayed BME 06:00:04 2024-05-22 EDT 5-day change 1st Jan Change
1.85 EUR +0.54% Intraday chart for Pangaea Oncology, S.A. +0.54% +0.54%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 13.8M 14.95M 20.44M Sales 2025 * 14.8M 16.03M 21.93M Capitalization 54.18M 58.7M 80.26M
Net income 2024 * -1M -1.08M -1.48M Net income 2025 * - 0 0 EV / Sales 2024 * 4.32 x
Net Debt 2024 * 5.5M 5.96M 8.15M Net Debt 2025 * 6.8M 7.37M 10.07M EV / Sales 2025 * 4.12 x
P/E ratio 2024 *
-36.8 x
P/E ratio 2025 *
-92 x
Employees 58
Yield 2024 *
-
Yield 2025 *
-
Free-Float 21.08%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.54%
1 week+0.54%
Current month+5.71%
1 month+6.94%
3 months+1.65%
6 months-0.54%
Current year+0.54%
More quotes
1 week
1.84
Extreme 1.84
1.85
1 month
1.69
Extreme 1.69
1.85
Current year
1.69
Extreme 1.69
1.91
1 year
1.68
Extreme 1.68
2.42
3 years
1.31
Extreme 1.31
2.42
5 years
0.97
Extreme 0.97
2.70
10 years
0.97
Extreme 0.97
3.50
More quotes
Managers TitleAgeSince
Founder - 06-12-31
Founder - 06-12-31
Founder - 06-12-31
Members of the board TitleAgeSince
Founder - 06-12-31
Founder - 06-12-31
Founder - 06-12-31
More insiders
Date Price Change Volume
24-05-22 1.85 +0.54% 1 819
24-05-21 1.84 0.00% 0
24-05-20 1.84 0.00% 0
24-05-17 1.84 0.00% 0
24-05-16 1.84 0.00% 0

Delayed Quote BME, May 22, 2024 at 06:00 am

More quotes
Pangaea Oncology SA is a Spain-based company primarily engaged in the biotechnology sector. The Company focuses on the development of oncology treatments. The Company’s activities are divided into two business lines: Clinical care in the Dr. Rosell Oncology Institute (IOR) and Molecular diagnosis (Dx). The IOR division offers personalized medical services related to oncology area, such as diagnosis, laboratory testing and treatment, in a chain of hospitals in Catalonia, Spain. The Dx division is responsible for the development of diagnostic and in-vitro services, biomarkers, as well as targeted drugs for patients and pharmaceutical companies. Its diagnostic models include Liquid Biopsy and Multiplexing.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Annual profits - Rate of surprise

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW